Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have received a consensus recommendation of “Hold” from the nine ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.00.
A number of analysts have issued reports on ACRX shares. ValuEngine raised AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Jefferies Group lowered AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Royal Bank of Canada cut their target price on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, October 13th. Piper Jaffray Companies reissued a “hold” rating and issued a $2.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, October 13th. Finally, Roth Capital set a $8.00 target price on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 12th.
AcelRx Pharmaceuticals (NASDAQ ACRX) traded down $0.17 during mid-day trading on Thursday, hitting $1.96. 867,010 shares of the stock traded hands, compared to its average volume of 974,947. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78. AcelRx Pharmaceuticals has a 1 year low of $1.55 and a 1 year high of $5.75.
In other AcelRx Pharmaceuticals news, insider Lawrence G. Hamel sold 10,161 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total value of $53,751.69. Following the sale, the insider now owns 16,379 shares of the company’s stock, valued at $86,644.91. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark G. Edwards bought 30,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was purchased at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the transaction, the director now owns 150,000 shares of the company’s stock, valued at $285,000. The disclosure for this purchase can be found here. 28.10% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Perennial Advisors LLC acquired a new position in shares of AcelRx Pharmaceuticals in the third quarter worth $138,000. Geller Family Office Services LLC acquired a new position in shares of AcelRx Pharmaceuticals in the third quarter worth $460,000. Virtu KCG Holdings LLC grew its stake in shares of AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares in the last quarter. LMR Partners LLP acquired a new position in shares of AcelRx Pharmaceuticals in the second quarter worth $319,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of AcelRx Pharmaceuticals in the second quarter worth $530,000. Institutional investors and hedge funds own 13.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/12/acelrx-pharmaceuticals-inc-acrx-receives-5-00-average-pt-from-brokerages.html.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.